Arbutus Biopharma (ABUS) logo

ABUS earnings date, and what happened the last 4 times

Next report

Mon Nov 16

Quality Score today 6

Before the open, in 21 days. Expected: the company has not confirmed it.

ABUS closed higher after 1 of its last 4 reports. On average it closed -0.8% the session after a report.

The moment ABUS reports

  • Its figures, in plain words
  • How it moves after, beside its last four
  • Its Quality Score going in, and after
Get an alert when ABUS reports, with its figures

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

What happened after ABUS's last 4 reports

ABUS's last 4 earnings reports
ReportedScore
going in
GapReaction
Aug 12, 20262026 · Before open10estimated-1.7%-1.7%
May 13, 20262026 · Before open10estimated+4.2%0.0%
Mar 23, 20262026 · Before open6estimated+2.8%+4.3%
Nov 13, 20252025 · Before open16estimated-1.2%-5.8%
  • Aug 12, 2026, before the open: that session ABUS opened -1.7% and closed -1.7%, and five sessions on it stood +3.6%. Its Quality Score going in was 10 (Average), estimated.
  • May 13, 2026, before the open: that session ABUS opened +4.2% and closed 0.0%, and five sessions on it stood -2.5%. Its Quality Score going in was 10 (Average), estimated.
  • Mar 23, 2026, before the open: that session ABUS opened +2.8% and closed +4.3%, and five sessions on it stood +1.2%. Its Quality Score going in was 6 (Average), estimated.
  • Nov 13, 2025, before the open: that session ABUS opened -1.2% and closed -5.8%, and five sessions on it stood -11.8%. Its Quality Score going in was 16 (Excellent), estimated.

Across these 4 reports ABUS opened higher after 2 of 4 and closed higher after 1 of 4; on average it opened +1.0%, closed -0.8%, and stood -2.4% five sessions on. Its Quality Score is 6 today, against 10 going into its Aug 12, 2026 report.

Gap: where the stock opened the session after the report. Reaction: where that session closed. Both against the close before the report. The largest of the 4: -5.8% after the Nov 13, 2025 report. A score marked estimated was worked out afterwards from that day's prices and filings; Breakaway has recorded every score live since Sep 9 2026.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Pro members see ABUS's reaction live as a report comes out, the release's figures, and an optional alert before it reports.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Questions about ABUS's earnings

As of Oct 26, 2026: Arbutus Biopharma (ABUS): expected to report Mon Nov 16, before the open. ABUS closed higher after 1 of its last 4 reports. Its Quality Score is 6 (Average). Scores as of 11:11 PM ET, 15 minutes behind.

When is ABUS's next earnings date?

Expected to report Mon Nov 16, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ABUS closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Does ABUS report before or after the market?

ABUS is expected to report Mon Nov 16, before the open. Its last 4 reports came before the open.

How did ABUS stock react to its last earnings report?

Aug 12, 2026, before the open: that session ABUS opened -1.7% and closed -1.7%, and five sessions on it stood +3.6%.

Does ABUS stock usually go up after earnings?

ABUS closed higher after 1 of its last 4 reports. On average it closed -0.8% the session after a report, after opening +1.0%. Past behavior, not a forecast.

Arbutus Biopharma's page has its Quality Score, its chart, and its insiders' trades. Who reports this week: the earnings calendar.

Past behavior, not a forecast. The score is delayed at least 15 minutes; the reports' moves are as they closed.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs; recorded live since Sep 9 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.